Skip to content

Nektar Therapeutics NKTR Business Segments — D&A

Similar metrics at other companies

Sarepta Therapeutics, Inc. logo
SRPTAll Other Segments — D&A
$10.59M+6.2%
BancFirst Corporation logo
BANFAll Other Segments — D&A
$150K+4.9%
Unifirst logo
UNFAll Other Segments — D&A
$818K+6.9%
Cheesecake Factory logo
CAKEAll Other Segments — D&A
$4.26M+5.8%
Rush Enterprises logo
RUSHBAll Other Segments — D&A
$148K+5.7%
Chemours logo
CCAll Segments — D&A
$74M-9.8%

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.25B+1,531%
Enterprise value$2.33B+874%
P/S40.5×+38.9×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's business segments — d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's business segments — D&A?
Nektar Therapeutics (NKTR) reported business segments — D&A of $121K in Q1 2026.
How has Nektar Therapeutics's business segments — D&A changed year-over-year?
Nektar Therapeutics's business segments — D&A decreased by 69.3% year-over-year, from $394K to $121K.
What is the long-term trend for Nektar Therapeutics's business segments — D&A?
Over 2 years (2023 to 2025), Nektar Therapeutics's business segments — D&A has grown at a -52.9% compound annual growth rate (CAGR), from $4.05M to $899K.
What does business segments — D&A mean?
Represents the systematic allocation of the cost of tangible and intangible assets over their useful lives within the segment. This non-cash expense reflects the consumption of capital investments required to support the segment's research, development, or operational activities. It is a key indicator of the segment's capital intensity and asset utilization.